Table 4 Proportion of studies examining potential biomarkers for disease activity that incorporated important study-design features
| Â | All diseases | SLE | RA | Other diseasesa |
|---|---|---|---|---|
| Â | n= 37 | n= 27 | n= 9 | n= 1 |
Study-design features | n (%) | n (%) | n (%) | n (%) |
Adjusted for age | 11 (29.7) | 10 (37.0) | 1 (11.1) | 0 |
Adjusted for sex | 12 (32.4) | 11 (40.7) | 1 (11.1) | 0 |
Adjusted for race | 16 (43.2) | 11 (40.7) | 4 (44.4) | 1 (100.0) |
Provided information on medications | 23 (62.1) | 18 (66.7) | 4 (44.4) | 1 (100.0) |
Controlled for treatment effects | 21 (56.8) | 16 (59.2) | 4 (44.4) | 0 |
Longitudinal component | 17 (45.9) | 11 (40.7) | 5 (55.6) | 1 (100.0) |
Validated disease-activity measures | 34 (91.9) | 27 (100.0) | 7 (77.8) | 0 |
Included wide range of disease activity | 34 (91.9) | 24 (88.9) | 9 (100.0) | 1 (100.0) |